11 June 2019

National Quality Registry for Systemic Psoriasis Treatment (PsoReg)

  • Registry Manager: Västerbotten County Council
  • Registry Centre - affiliation: Registry Centre North, RCN
  • Start year: 2007
  • Classifications used: ICD10, ATC (pharmaceuticals)
  • This registry contains data on: Pharmaceuticals, Diagnoses, Specialised Outpatient Care, PROM or other patient-reported health effects, Risk Factors

Description of registry

The aim of the registry is to include all psoriasis patients in the country who receive systemic therapy. In our most urgent target group – patients receiving biological therapy with treatment costs of approximately SEK 130,000 per patient and year – over half of country’s patients are registered.

Systemic treatment entails potential risks for the patients and it is unfortunate that we have not previously been able to monitor how recommendations for the treatment have been applied. Procedures for initiation of treatment, drug dosage, sampling, etc. can vary considerably throughout the country. A national evaluation of forms of treatment is urgent with regard to the benefit of therapy for both patients and for society at large from a health economics standpoint.

A national registry is essential in order to gain, as quickly as possible, important experience-based information regarding drug limitations, such as serious side effects.

PsoReg’s aims:

  • to continually improve psoriasis care in Sweden with a focus on patient safety, equitable care, health economics and indication monitoring (under-treatment vs. indication shift)
  • to evaluate the efficacy and safety of systemic medicines for different types of psoriasis
  • to contribute to quality improvements in care by enabling comparisons between the clinic’s methods for managing patients in regard to choice of therapy and treatment monitoring
  • to provide feedback to healthcare providers on knowledge gained
  • to add a public health perspective to psoriasis care and call attention to the significance of factors such as BMI, smoking and alcohol use on the skin disease and on the efficacy of initiated drugs
  • to guide healthcare providers in the selection of the most effective therapy at the lowest cost


Our primary target group is psoriasis patients who are candidates for systemic treatment and this group is primarily treated by dermatologists, i.e. in specialist care. Secondly, there is a vision to expand the patient base and then also include psoriasis patients receiving conventional light therapy (UVB) in order to evaluate the benefits, long-term effects and side effects of this treatment and make comparisons with systemic treatment.

Ages in the registry

All ages.

Note: Variable lists are updated on a regular basis and should therefore be seen as preliminary. For the latest version, please contact the registry.

Category: Other areas

Certification level: 2

Read more

Hjälpte informationen på sidan dig?

Tack för att du hjälper oss!